|
| Status |
Public on Nov 15, 2018 |
| Title |
Gene expression data of glioblastoma patients from GAPVAC trial (Glioma Actively Personalized Vaccine Consortium) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Patients with glioblastoma (GB) so far do not sufficiently benefit from recent breakthroughs with checkpoint inhibitors (CPI), for which high mutational load and responses to neo-epitopes are regarded essential. GB tumours show limited intra-tumoral immune cell infiltration and carry 30-50 non-synonymous mutations only. Exploitation of the full repertoire of tumour antigens - non-mutated and neo-epitopes – may offer more effective immunotherapies, especially for tumours with low mutational load. In the first-in-human trial GAPVAC-101, the Glioma Actively Personalized Vaccine Consortium (GAPVAC) integrated both tracks highly individualized into standard treatment to optimally exploit the limited target space for patients with newly diagnosed GB. Fifteen HLA-A*02:01+ or -A*24:02+ patients were treated with a warehouse-based vaccine (APVAC1) targeting non-mutated antigens followed by APVAC2, targeting preferentially neo-epitopes. Personalization was based on mutations, transcriptome, and immunopeptidome of the individual tumours. The GAPVAC approach was feasible and vaccinations adjuvanted by poly-ICLC and GM-CSF displayed favourable safety and excellent immunogenicity: Non-mutated APVAC1 antigens induced sustained central memory CD8+ T-cell responses. APVAC2 induced predominantly TH1 CD4+ T-cell responses against predicted neo-epitopes.
www.GAPVAC.eu
|
| |
|
| Overall design |
mRNA of 16 patients were analyzed and normalized against a normal kidney sample used as reference
contributor: GAPVAC (Glioma Actively Personalized Vaccine Consortium)
|
| |
|
| Contributor(s) |
Fritsche J |
| Citation(s) |
30568303 |
| |
| Submission date |
Nov 14, 2018 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Wolfgang Wick |
| Organization name |
Ruprecht-Karls University Heidelberg
|
| Department |
Neurooncology
|
| Street address |
Im Neuenheimer Feld 400
|
| City |
Heidelberg |
| ZIP/Postal code |
69120 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (17)
|
|
| Relations |
| BioProject |
PRJNA505415 |
Less...
More...